ArticleInternational journal of cardiology. Cardiovascular risk and prevention2026
Association between psychiatric comorbidities and the pharmacological secondary prevention of ischemic heart disease and cerebrovascular disease - an analysis of real-world health insurance prescription data in Germany.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individuals with mental disorders face substantially reduced life expectancy, with cardiovascular disease (CVD) as the leading cause of premature death, likely due to a complex interplay of multiple factors. Prior studies examining whether patients with comorbid mental illness receive guideline-concordant pharmacological secondary prevention of ischemic heart disease (IHD) and cerebrovascular disease (CeVD) at rates comparable to those without psychiatric diagnoses are few and yielded inconsistent findings. Methods: We conducted a retrospective cross-sectional analysis of statutory health insurance data for 2019-2022 (n = 238,616 adults with IHD or CeVD). Secondary prevention was defined as concurrent prescription of a lipid-modifying agent and an antiplatelet therapy or anticoagulant. Propensity score matching combined with logistic regression was used to estimate adjusted odds ratios (ORs) across all ICD-10 F-chapters (F0-F9) and for severe mental illness (SMI). Results: Patients with any mental disorder had significantly higher odds of receiving secondary prevention for IHD (OR 1.18) and CeVD (OR 1.17) than those without. SMI was associated with even higher odds (IHD: OR 1.36; CeVD: OR 1.32). Diagnosis-specific subgroup analysis yielded no substantial differences between different mental disorders. Conclusion: In general, prescription rates of pharmacological secondary prevention were higher in patients with comorbid mental disorders compared to patients without mental comorbidity. Factors other than pharmacological undertreatment - such as lifestyle-related prevention and physical health monitoring - may play a more central role in addressing the excess cardiovascular mortality burden in individuals with mental illness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.